Adamas Pharmaceuticals Inc (ADMS) Gross Profit Margin starting from the third quarter 2021 to third quarter 2020, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Adamas Pharmaceuticals Inc  (NASDAQ: ADMS)


Adamas Pharmaceuticals Inc's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ADMS Gross Profit Margin (Sep 30 2021)
Q3 		(Jun 30 2021)
Q2 		(Mar 31 2021)
Q1 		(Dec 31 2020)
Q4 		(Sep 30 2020)
Q3
Y / Y Revenue Change 28.35 %
Seq. Revenue Change 17.86 %
Revenue In Millions $25.90
Gross Profit Margin 97.78 %
Gross Profit Margin Total Ranking # 85
Gross Profit In Millions $25.32
Y / Y Gross Profit Change 28.61 %
Seq. Gross Profit Change 18.07 %


Commenting Third Quarter 2021 Gross Profit Margin
Adamas Pharmaceuticals Inc Gross Profit grew by 18.07 % in Q3 sequentially to 25 millions, while Revenue increased by 17.86 %, this led to improvement in the company's Gross Profit Margin to 97.78 %, above the Adamas Pharmaceuticals Inc average Gross Profit Margin.


Observing third quarter 2021 results within Major Pharmaceutical Preparations industry 14 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 85, from total ranking in the previous quarter at 97.
Learn about Gross Margin
ADMS's Gross Profit Margin third quarter 2021 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 15
Healthcare Sector # 18
Overall # 81

Gross Profit Margin Statistics
High Average Low
99.06 % 97.17 % 93.33 %
(Sep 30 2018)   (Sep 30 2019)


ADMS Gross Income Trends • More of ADMS's Profitabilty Ratios • ADMS Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
ADMS's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
ADMS's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for ADMS's Competitors
Gross Profit Margin Profit Margin for Adamas Pharmaceuticals Inc's Suppliers
Gross Profit Margin Profit Margin for ADMS's Customers

You may also want to know
ADMS's Annual Growth Rates ADMS's Profitability Ratios ADMS's Asset Turnover Ratio ADMS's Dividend Growth
ADMS's Roe ADMS's Valuation Ratios ADMS's Financial Strength Ratios ADMS's Gross Profit Growth
ADMS's Roa ADMS's Inventory Turnover Ratio ADMS's Growth Rates ADMS's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2021, within Major Pharmaceutical Preparations Industry Gross Profit MarginSep 30 2021 MRQ Gross ProfitSep 30 2021 MRQ Revenue
Biora Therapeutics Inc   100.00 %$ 0.182  Millions$ 0.182  Millions
Ptc Therapeutics inc   99.64 %$ 138.243  Millions$ 138.743  Millions
Abvc Biopharma Inc   99.60 %$ 0.099  Millions$ 0.099  Millions
Karyopharm Therapeutics Inc   99.47 %$ 37.489  Millions$ 37.689  Millions
Rigel Pharmaceuticals Inc  99.30 %$ 21.392  Millions$ 21.543  Millions
Intercept Pharmaceuticals inc   99.29 %$ 92.169  Millions$ 92.827  Millions
Biofrontera Inc   99.05 %$ 4.293  Millions$ 4.334  Millions
Omeros Corporation  98.89 %$ 29.671  Millions$ 30.004  Millions
Corcept Therapeutics Inc  98.67 %$ 94.856  Millions$ 96.131  Millions
Global Blood Therapeutics Inc.  98.41 %$ 51.222  Millions$ 52.052  Millions
2seventy Bio Inc   98.34 %$ 18.937  Millions$ 19.257  Millions
Siga Technologies Inc  98.28 %$ 4.763  Millions$ 4.846  Millions
Aurinia Pharmaceuticals Inc   98.27 %$ 14.413  Millions$ 14.667  Millions
Kyntra Bio Inc   97.91 %$ 152.707  Millions$ 155.973  Millions
Adamas Pharmaceuticals Inc  97.78 %$ 25.320  Millions$ 25.896  Millions
Ionis Pharmaceuticals Inc   97.69 %$ 130.014  Millions$ 133.093  Millions
Travere Therapeutics Inc   97.67 %$ 66.625  Millions$ 68.217  Millions
Cytodyn inc   97.56 %$ 0.040  Millions$ 0.041  Millions
Acadia Pharmaceuticals Inc   97.20 %$ 127.924  Millions$ 131.612  Millions
Myovant Sciences Ltd   96.63 %$ 75.280  Millions$ 77.902  Millions
Deciphera Pharmaceuticals Inc   96.05 %$ 22.303  Millions$ 23.220  Millions
Kadmon holdings inc   95.63 %$ 14.063  Millions$ 14.706  Millions
Ultragenyx Pharmaceutical Inc   94.89 %$ 77.472  Millions$ 81.647  Millions
Zogenix Inc   94.28 %$ 21.316  Millions$ 22.610  Millions
Celularity Inc   93.99 %$ 9.984  Millions$ 10.622  Millions
Y mabs Therapeutics inc   93.87 %$ 8.415  Millions$ 8.965  Millions
United Therapeutics Corporation  93.77 %$ 417.000  Millions$ 444.700  Millions
Regeneron Pharmaceuticals Inc   93.08 %$ 3,214.000  Millions$ 3,452.800  Millions
Emmaus Life Sciences Inc   92.28 %$ 5.321  Millions$ 5.766  Millions
Silo Pharma Inc  91.91 %$ 0.017  Millions$ 0.018  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.